These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29282764)

  • 1. Sample size determination for jointly testing a cause-specific hazard and the all-cause hazard in the presence of competing risks.
    Yang Q; Fung WK; Li G
    Stat Med; 2018 Apr; 37(8):1389-1401. PubMed ID: 29282764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating sample size in the presence of competing risks - Cause-specific hazard or cumulative incidence approach?
    Tai BC; Chen ZJ; Machin D
    Stat Methods Med Res; 2018 Jan; 27(1):114-125. PubMed ID: 26711503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons.
    Cantagallo E; De Backer M; Kicinski M; Ozenne B; Collette L; Legrand C; Buyse M; Péron J
    Biom J; 2021 Feb; 63(2):272-288. PubMed ID: 32939818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size calculations in the presence of competing risks.
    Latouche A; Porcher R
    Stat Med; 2007 Dec; 26(30):5370-80. PubMed ID: 17955563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential trials in the context of competing risks: Concepts and case study, with R and SAS code.
    Baayen C; Volteau C; Flamant C; Blanche P
    Stat Med; 2019 Aug; 38(19):3682-3702. PubMed ID: 31099906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Competing time-to-event endpoints in cardiology trials: a simulation study to illustrate the importance of an adequate statistical analysis.
    Rauch G; Kieser M; Ulrich S; Doherty P; Rauch B; Schneider S; Riemer T; Senges J
    Eur J Prev Cardiol; 2014 Jan; 21(1):74-80. PubMed ID: 22964966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of an Alternative Method for Assessing Competing Risks: Restricted Mean Time Lost.
    Wu H; Yuan H; Yang Z; Hou Y; Chen Z
    Am J Epidemiol; 2022 Jan; 191(1):163-172. PubMed ID: 34550319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sample sizes for clinical trials with time-to-event endpoints and competing risks.
    Schulgen G; Olschewski M; Krane V; Wanner C; Ruf G; Schumacher M
    Contemp Clin Trials; 2005 Jun; 26(3):386-96. PubMed ID: 15911472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Communicating and understanding statistical measures when quantifying the between-group difference in competing risks.
    Wu H; Zhang C; Hou Y; Chen Z
    Int J Epidemiol; 2023 Dec; 52(6):1975-1983. PubMed ID: 37738672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subgroup detection and sample size calculation with proportional hazards regression for survival data.
    Kang S; Lu W; Song R
    Stat Med; 2017 Dec; 36(29):4646-4659. PubMed ID: 28791726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size determination for comparing several survival curves with unequal allocations.
    Halabi S; Singh B
    Stat Med; 2004 Jun; 23(11):1793-815. PubMed ID: 15160409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample size determination for comparing more than two survival distributions.
    Ahnn S; Anderson SJ
    Stat Med; 1995 Oct; 14(20):2273-82. PubMed ID: 8552903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample Size Calculation Under Nonproportional Hazards Using Average Hazard Ratios.
    Dormuth I; Pauly M; Rauch G; Herrmann C
    Biom J; 2024 Sep; 66(6):e202300271. PubMed ID: 39132909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size re-estimation for survival data in clinical trials with an adaptive design.
    Togo K; Iwasaki M
    Pharm Stat; 2011; 10(4):325-31. PubMed ID: 22328325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of censoring in competing risks analysis of the subdistribution hazard.
    Donoghoe MW; Gebski V
    BMC Med Res Methodol; 2017 Apr; 17(1):52. PubMed ID: 28376736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantifying time-varying cause-specific hazard and subdistribution hazard ratios with competing risks data.
    Diao G; Ibrahim JG
    Clin Trials; 2019 Aug; 16(4):363-374. PubMed ID: 31165631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Power and sample size calculation for log-rank test with a time lag in treatment effect.
    Zhang D; Quan H
    Stat Med; 2009 Feb; 28(5):864-79. PubMed ID: 19152230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.
    Xiong X; Wu J
    Pharm Stat; 2017 Jan; 16(1):87-94. PubMed ID: 27860138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of restricted mean time lost under competing risks data.
    Lyu J; Hou Y; Chen Z
    BMC Med Res Methodol; 2020 Jul; 20(1):197. PubMed ID: 32711456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Instrumental variable with competing risk model.
    Zheng C; Dai R; Hari PN; Zhang MJ
    Stat Med; 2017 Apr; 36(8):1240-1255. PubMed ID: 28064466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.